Volume 12 Supplement 1
Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from subtype-C HIV-1 infected north Indians; implications for MPER directed HIV-1 neutralization
© Andrabi et al; licensee BioMed Central Ltd. 2012
Published: 4 May 2012
Evaluation of the broad and potent neutralizing antibody (bNAb) responses in sera of HIV-1 infected individuals is important for immunogen design.
Plasma of eighty naïve HIV-1 seropositive Indian patients were tested for neutralization against a panel of 3 subtype-B and 5 subtype-C tier 1 and tier 2 viruses. Three plasma, found to be broadly neutralizing (bNP), were mapped with a set of 212 consensus-C gp160 overlapping peptides (15mer each). 50% binding titers were determined by ELISA using consensus-C V3 (35mer), IDR loop (19mer) and MPER (24mer) peptides.
The patients (30 females and 50 males; age range: 20-57 years) had been infected for different time periods (few days to seven years). The viral load ranged from 156-2180000 RNA copies/ml; mean CD4 count was 346 cells/mm3 while mean total IgG levels was 12.3 mg/ml. 64 plasma (80%) neutralized at least one virus while 16 (20%) did not show any neutralization. Three plasma samples AIIMS206, AIIMS239 and AIIMS249 neutralized all eight viruses tested. Subtype-specific neutralization predominated, plasma antibodies being more effective against subtype-C than subtype-B viruses (p=0.004). Epitope specificities of the three bNP mapped to V2, V3 and C5 of gp120 and ID region, MPER and CT of gp41. Depletion and competition with V3, MPER and IDR peptides showed modest effect on neutralization except for AIIMS239 which showed dependence on MPER directed antibodies with most viruses.
Reactivity to the highly immunogenic V3 region showed dependence on plasma viremia. Anti-MPER antibodies may play a crucial role in HIV-1 clade C viral neutralization.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.